Global Combined Hormonal Contraceptives Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Combined Hormonal Contraceptives Sales Market Report 2024
Market Analysis and InsightsGlobal Combined Hormonal Contraceptives Market
Combined hormonal contraceptives are used to prevent pregnancies. They are also used in the treatment of acne vulgaris, endometriosis, polycystic ovarian syndrome, and irregular menstrual flow by blocking ovulation. These products are widely used by women of aged between 15 and 49 years.
Due to the COVID-19 pandemic, the global Combined Hormonal Contraceptives market size is estimated to be worth US$ 17780 million in 2024 and is forecast to a readjusted size of US$ 22360 million by 2034 with a CAGR of 3.3% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, 15-24 years accounting for % of the Combined Hormonal Contraceptives global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
The United States Combined Hormonal Contraceptives market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Combined Hormonal Contraceptives include Actavis, Agile Therapeutics, Allergan, Bayer, Teva Pharmaceutical Industries, ANI Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Noven Pharmaceuticals and Johnson & Johnson, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Combined Hormonal Contraceptives Scope and Market Size
The global Combined Hormonal Contraceptives market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Combined Hormonal Contraceptives market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
15-24 years
25-34 years
35-44 years
Above 44 years
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Actavis
Agile Therapeutics
Allergan
Bayer
Teva Pharmaceutical Industries
ANI Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Noven Pharmaceuticals
Johnson & Johnson
Mylan
Combined hormonal contraceptives are used to prevent pregnancies. They are also used in the treatment of acne vulgaris, endometriosis, polycystic ovarian syndrome, and irregular menstrual flow by blocking ovulation. These products are widely used by women of aged between 15 and 49 years.
Due to the COVID-19 pandemic, the global Combined Hormonal Contraceptives market size is estimated to be worth US$ 17780 million in 2024 and is forecast to a readjusted size of US$ 22360 million by 2034 with a CAGR of 3.3% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, 15-24 years accounting for % of the Combined Hormonal Contraceptives global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
The United States Combined Hormonal Contraceptives market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Combined Hormonal Contraceptives include Actavis, Agile Therapeutics, Allergan, Bayer, Teva Pharmaceutical Industries, ANI Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Noven Pharmaceuticals and Johnson & Johnson, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Combined Hormonal Contraceptives Scope and Market Size
The global Combined Hormonal Contraceptives market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Combined Hormonal Contraceptives market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
15-24 years
25-34 years
35-44 years
Above 44 years
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Actavis
Agile Therapeutics
Allergan
Bayer
Teva Pharmaceutical Industries
ANI Pharmaceuticals
Ortho-McNeil-Janssen Pharmaceuticals
Noven Pharmaceuticals
Johnson & Johnson
Mylan
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices